COSCIENS Biopharma Inc
CSCI3.965USD
+0.145+3.80%
시장 운영 시간 （ET）시세는 15분 지연됩니다
12.47M시가총액
손실P/E TTM
자세한 내용은 COSCIENS Biopharma Inc 회사
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
회사 정보
종목 코드 CSCI
회사 이름COSCIENS Biopharma Inc
상장일Dec 19, 1995
CEOMs. Anna Biehn
직원 수- -
유형Ordinary Share
회계 연도 종료Dec 19
주소C/O Norton Rose Fulbright Canada Llp
도시TORONTO
증권 거래소The Toronto Stock Exchange
국가Canada
우편 번호M5K 1E7
전화18439003201
웹사이트https://www.cosciensbio.com/
종목 코드 CSCI
상장일Dec 19, 1995
CEOMs. Anna Biehn
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Ms. Genevieve Foster
Ms. Genevieve Foster
Director
Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Director
Director
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Chairman of the Board
Chairman of the Board
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Apr 6
통화: USD마지막 업데이트: Sun, Apr 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
데이터 없음
지역별USD
이름
수익
비율
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, Aug 1
마지막 업데이트: Fri, Aug 1
주주
주주 유형
주주
주주
비율
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
주주
주주
비율
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
8.19%
Individual Investor
1.49%
Investment Advisor
0.70%
Research Firm
0.11%
Bank and Trust
0.04%
Other
89.47%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
2023Q2
52
14.44K
1.19%
-13.85K
2023Q1
54
14.56K
1.20%
-15.46K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Goodwood Inc.
257.26K
8.18%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.33%
--
--
Mar 26, 2025
Susquehanna International Group, LLP
11.91K
0.38%
+11.91K
--
Mar 31, 2025
RBC Dominion Securities, Inc.
3.87K
0.12%
-69.00
-1.75%
Mar 31, 2025
TD Waterhouse Canada, Inc.
3.72K
0.12%
--
--
Mar 31, 2025
Desjardins Securities Inc.
2.81K
0.09%
-1.06K
-27.39%
Mar 31, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
UBS Financial Services, Inc.
2.34K
0.07%
+1.65K
+240.67%
Mar 31, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
National Bank of Canada
1.12K
0.04%
-4.80K
-81.05%
Mar 31, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
날짜
유형
비율
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
